Charles Darwin University

CDU eSpace
Institutional Repository

 
CDU Staff and Student only
 

Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months age, a randomized controlled trial

Russell, Fiona, Carapetis, Jonathan R., Balloch, Anne, Licciardi, Paul V., Jenney, Adam, Tikoduadua, Lisi, Waqatakirewa, Lepani, Pryor, Jan, Nelson, Jane N., Byrnes, Graham, Cheung, Yin, Tang, Mimi and Mulholland, E. Kim (2010). Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months age, a randomized controlled trial. Vaccine,28(19):3341-3349.

Document type: Journal Article

IRMA ID 81704288xPUB52
Title Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months age, a randomized controlled trial
Author Russell, Fiona
Carapetis, Jonathan R.
Balloch, Anne
Licciardi, Paul V.
Jenney, Adam
Tikoduadua, Lisi
Waqatakirewa, Lepani
Pryor, Jan
Nelson, Jane N.
Byrnes, Graham
Cheung, Yin
Tang, Mimi
Mulholland, E. Kim
Journal Name Vaccine
Publication Date 2010
Volume Number 28
Issue Number 19
ISSN 0264-410X   (check CDU catalogue  open catalogue search in new window)
Start Page 3341
End Page 3349
Total Pages 8
Place of Publication United Kingdom
Publisher Elsevier Ltd
HERDC Category C1 - Journal Article (DIISR)
Abstract BACKGROUND:
To evaluate the immunological impact of the 23-valent pneumococcal polysaccharide vaccine (23vPPS) at 12 months, for children who have received zero to three infant doses of seven-valent pneumococcal conjugate vaccine (PCV), on responses to a subsequent exposure to a small dose of 23vPPS (mPPS).

METHODS:

Five hundred and fifty-two Fijian infants were stratified by ethnicity and randomized into eight groups to receive zero, one, two, or three PCV doses at 14 weeks, six and 14 weeks, or six, ten, and 14 weeks. Within each group, half received 23vPPS at 12 months and all received mPPS at 17 months. Sera were taken prior and one month post-mPPS.

FINDINGS:

By 17 months, geometric mean antibody concentrations (GMC) to all 23 serotypes in 23vPPS were significantly higher in children who had received 23vPPS at 12 months compared to those who had not. Post-mPPS, children who had not received the 12 month 23vPPS had a significantly higher GMC for all PCV serotypes compared with those who had (each p<0.02). For the non-PCV serotypes, children who had not received the 12 month 23vPPS had significantly higher GMC for six of 16 non-PCV serotypes (7F, 9N, 12F, 19A, 22F, 33F) than those who did (each p<0.02). After adjusting for the pre-mPPS level, exposure to 23vPPS was associated with a lower response to mPPS for all serotypes (each p<0.001).

INTERPRETATION:

Despite higher antibody concentrations at 17 months in children who had received 23vPPS at 12 months, the response to a re-challenge was poor for all 23 serotypes compared to children who had not received the 12 month 23vPPS.
Keywords Pneumococcal vaccines
Immunogenicity
Hyporesponsiveness
DOI http://dx.doi.org/10.1016/j.vaccine.2010.02.087   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
 
Versions
Version Filter Type
Access Statistics: 24 Abstract Views  -  Detailed Statistics
Created: Fri, 17 Jan 2014, 00:39:42 CST